Paris, France and Camberley, UK – 4 February 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it is launching a new Performance Share Awards programme for executive management as part of its new Long Term Incentive Plan (“LTIP”). This new LTIP replaces the previous phantom share
Visit PageCategory: Novacyt Group
Strategy and Full Year 2021 Trading Update and Interview with David Allmond
Full year revenue and EBITDA in line with expectationsCommitted to becoming a leading, global clinical diagnostics company Paris, France and Camberley, UK – 25 January 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2021, together with a strategy
Visit PageApproval of COVID-19 test in the UK under CTDA legislation
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021
Visit Page